DE | Accessible presentation
Translations are powered by AI

These Munich startups are ripe for investment

Which startups have the best prospects of successfully completing a financing round soon? We take a look into the crystal ball and introduce you to five companies that are ripe for investment.

February 19, 2024 4 min reading time

Tubules
Tubules develops so-called antibody-drug conjugates (ADCs) designed to attack tumors. These compounds enable the targeted delivery of substances to the tissue affected by a disease. In the case of cancer, this enables, for example, the targeted delivery of chemotherapeutic agents to cancer cells without releasing large amounts of toxic substances into healthy tissue. The company, founded in 2019 as a spin-off of the Leibniz Research Institute Berlin (FMP) and the Ludwig Maximilian University (LMU), focuses on stabilizing these ADCs in order to expand their potential applications. In May 2022, Tubules raised another €60 million in its Series B, increasing its total funding to approximately €72 million. The dealroom signal achieved 71 points, but with a full 100 points in the "timing" category. (Image: Carolin Bleese)
read more ↓